Established Pharmaceuticals sales increased almost 8% on an organic basis (6.9% reported), with double-digit increases in several countries across Asia, Latin America and the Middle East. Strong demand for Ensure and Glucerna fueled more than 6% organic growth in Adult Nutrition (6.1% reported), leading overall Nutrition sales performance.<\/p>\n
<\/p>\n
Adjusted diluted earnings per share (EPS) was $1.26, reflecting double-digit growth compared to the prior year (GAAP diluted EPS was $1.01). We narrowed our full-year 2025 adjusted diluted EPS guidance3 range to $5.10 to $5.20, which reflects double-digit growth at the midpoint of $5.15. Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0% or 6.0% to 7.0%, when including COVID-19 testing-related sales.<\/p>\n
<\/p>\n
During the second quarter, we continued to advance our pipeline with purpose, delivering on our mission to broaden the impact of our breakthrough technologies. Notable milestones include:<\/p>\n
For full financial data and reconciliation of non-GAAP measures, you can read Abbott\u2019s full press release<\/a>.<\/p>\n
<\/p>\n
\nCompleted enrollment in the U.S. IDE trial for the TactiFlex\u2122 Duo Pulsed Field Ablation (PFA) System\u2014which is being evaluated for the treatment of patients with heart rhythm disorders such as atrial fibrillation.Announced clinical data from the AVEIR\u2122 Conduction System Pacing (CSP)<\/a> feasibility study\u2014the world’s first evaluation of a leadless pacemaker capable of delivering conduction pacing that closely mimics the heart’s natural rhythm.Received FDA approval for our Tendyne\u2122 transcatheter mitral valve replacement (TMVR) system<\/a>\u2014the first device of its kind designed to replace the mitral valve without the need for open-heart surgery.Initiated development of a new cardiovascular device manufacturing facility\u2014located in the state of Georgia to be completed by 2028.
<\/p>\n